FAST NEWS: Connect Biopharma Plunges on Poor Results for Colitis Drug
The latest: Connect Biopharma (CNTB.US) said late on Tuesday that results from a Phase 2 trial for its CBP-307 drug for treatment of patients with moderate to severe ulcerative colitis…
RELATED ARTICLES
-
Kintor shares plunge after hair-loss drug flops in clinical trials
9939.HK
-
Everest reaches new heights on growing drug sales
1952.HK
- HighTide Therapeutics places big IPO bet on “affluenza” drug
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
-
With its sale to AstraZeneca, Gracell blazes exit trail for cash-challenged Chinese biotechs
GRCL.US
-
Drug maker Junshi seeks Swiss cure for cash woes
1877.HK 688150.SHG
Discover hidden China stock gems in our weekly newsletter